Pioglitazone wins out over rosiglitazone in type 2 diabetes

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1571, 2007-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pioglitazone wins out over rosiglitazone in type 2 diabetes

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 519, 2007-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK

By Home Philip  

PharmacoEconomics, Vol. 25, Iss. 9, 2007-01 ,pp. : 801-802

Adis International

Access to resources Recommend Favorite

A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK

By Tilden Dominic P.  

PharmacoEconomics, Vol. 25, Iss. 1, 2007-01 ,pp. : 39-54

Adis International

Access to resources Recommend Favorite

Effects of Rosiglitazone and Pioglitazone Combined with Metformin on the Prothrombotic State of Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome

By Derosa G   D'Angelo A   Ragonesi PD   Ciccarelli L   Piccinni MN   Pricolo F   Salvadeo S   Montagna L   Gravina A   Ferrari I   Galli S   Paniga S   Cicero AFG  

The Journal of International Medical Research, Vol. 34, Iss. 5, 2006-09 ,pp. : 545-555

Field House Publishing

Access to resources Recommend Favorite

Spotlight on pioglitazone in type 2 diabetes

By  

Inpharma, Vol. 1, Iss. 1268, 2000-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite